Abstract
Donepezil (Aricept®), a long-acting cholinesterase inhibitor, is widely used in the treatment of Alzheimer's disease to improve cognition and memory. Many drugs within the class of cognition-enhancing agents, both currently approved medications and those under development, have clinical indications narrowly relegated to Alzheimer's disease. The purpose of this study was to determine whether the efficacy attributed to donepezil in its ability to improve delayed matching accuracy by monkeys was independent of age. Male and female rhesus monkeys (n = 17) ranging from 9 to 29 yr of age were administered donepezil (10, 25, 50, and 100 μg/kg, im) during 4 discrete test days. Donepezil treatment improved average task accuracy, but intersubject variability prohibited statistical significance. When animals were considered individually, the most effective dose of donepezil was associated with a highly significant increase in group task performance that was consistent with enhanced recall during testing. The variability associated with the dose-response analysis was attributable primarily to subject age, such that older monkeys required higher doses of donepezil. Yet at doses that were effective in all subjects, there was no relationship between age and the improvement in task accuracy. Likewise, there was no association between baseline task proficiency and improvement in task accuracy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 85-91 |
| Number of pages | 7 |
| Journal | Journal of Molecular Neuroscience |
| Volume | 24 |
| Issue number | 1 |
| State | Published - Aug 1 2004 |
Fingerprint
Keywords
- Aging
- Cholinesterase inhibitor
- Cognition
- Delayed matching
- Donepezil
- Memory
- Nonhuman primate
- Recall
ASJC Scopus subject areas
- Cellular and Molecular Neuroscience
Cite this
Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys. / Buccafusco, Jerry J.; Terry, Alvin V.
In: Journal of Molecular Neuroscience, Vol. 24, No. 1, 01.08.2004, p. 85-91.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys
AU - Buccafusco, Jerry J.
AU - Terry, Alvin V
PY - 2004/8/1
Y1 - 2004/8/1
N2 - Donepezil (Aricept®), a long-acting cholinesterase inhibitor, is widely used in the treatment of Alzheimer's disease to improve cognition and memory. Many drugs within the class of cognition-enhancing agents, both currently approved medications and those under development, have clinical indications narrowly relegated to Alzheimer's disease. The purpose of this study was to determine whether the efficacy attributed to donepezil in its ability to improve delayed matching accuracy by monkeys was independent of age. Male and female rhesus monkeys (n = 17) ranging from 9 to 29 yr of age were administered donepezil (10, 25, 50, and 100 μg/kg, im) during 4 discrete test days. Donepezil treatment improved average task accuracy, but intersubject variability prohibited statistical significance. When animals were considered individually, the most effective dose of donepezil was associated with a highly significant increase in group task performance that was consistent with enhanced recall during testing. The variability associated with the dose-response analysis was attributable primarily to subject age, such that older monkeys required higher doses of donepezil. Yet at doses that were effective in all subjects, there was no relationship between age and the improvement in task accuracy. Likewise, there was no association between baseline task proficiency and improvement in task accuracy.
AB - Donepezil (Aricept®), a long-acting cholinesterase inhibitor, is widely used in the treatment of Alzheimer's disease to improve cognition and memory. Many drugs within the class of cognition-enhancing agents, both currently approved medications and those under development, have clinical indications narrowly relegated to Alzheimer's disease. The purpose of this study was to determine whether the efficacy attributed to donepezil in its ability to improve delayed matching accuracy by monkeys was independent of age. Male and female rhesus monkeys (n = 17) ranging from 9 to 29 yr of age were administered donepezil (10, 25, 50, and 100 μg/kg, im) during 4 discrete test days. Donepezil treatment improved average task accuracy, but intersubject variability prohibited statistical significance. When animals were considered individually, the most effective dose of donepezil was associated with a highly significant increase in group task performance that was consistent with enhanced recall during testing. The variability associated with the dose-response analysis was attributable primarily to subject age, such that older monkeys required higher doses of donepezil. Yet at doses that were effective in all subjects, there was no relationship between age and the improvement in task accuracy. Likewise, there was no association between baseline task proficiency and improvement in task accuracy.
KW - Aging
KW - Cholinesterase inhibitor
KW - Cognition
KW - Delayed matching
KW - Donepezil
KW - Memory
KW - Nonhuman primate
KW - Recall
UR - http://www.scopus.com/inward/record.url?scp=16544394141&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=16544394141&partnerID=8YFLogxK
M3 - Article
C2 - 15314255
AN - SCOPUS:16544394141
VL - 24
SP - 85
EP - 91
JO - Journal of Molecular Neuroscience
JF - Journal of Molecular Neuroscience
SN - 0895-8696
IS - 1
ER -